Personalised mRNA Melanoma Vaccine Posts Positive Phase 3 Result

Key Points

  • In the Phase 3 INTerpath-001 trial, adding intismeran to Keytruda reduced the risk of recurrence or death by 42% compared with Keytruda alone.
  • Two years in, 82.2% of the combination group were alive without recurrence, against 70.0% on Keytruda alone.
  • Overall survival data "were immature and did not meet the prespecified significance boundary".
  • As of 31 October 2026 the treatment is investigational, and Merck says it is engaging with regulatory authorities.

Published .

A blue clad building with a curved glass corner at a road junction on the Western General Hospital site in Edinburgh, beside a site sign for the Carrington Crescent entrance, with concrete and blue clad buildings behind and cars parked along the road under a grey sky.
The Western General Hospital in Edinburgh, 24 June 2013. Photo: John Lord, CC BY-SA 2.0, via Wikimedia Commons, resized, photo source.

Merck and Moderna released the detailed results of their Phase 3 INTerpath-001 trial on 22 October 2026. Adding intismeran autogene, a personalised mRNA treatment, to the immunotherapy Keytruda (pembrolizumab) reduced the risk of recurrence or death by 42%1 compared with Keytruda alone, in people whose stage IIB to IV melanoma had been completely removed by surgery. The data were presented as a late-breaking abstract (LBA1) during Presidential Symposium I5 at the ESMO Congress, the European Society for Medical Oncology meeting held in Madrid from 23 to 27 October3.

The headline came first on 19 August, when the companies said the trial met its primary endpoint of recurrence-free survival2 at a pre-specified interim analysis. They called it "the first positive Phase 3 readout for an individualized neoantigen therapy (INT) and for an mRNA-based cancer therapy"2. As of 31 October 2026 the treatment is still investigational1, and the UK chief investigator, Heather Shaw of University College London Hospitals, said it "remains an experimental treatment and is not currently available on the NHS"7.

Treatment after surgery

Surgery can remove a melanoma, but the cancer can still return, and that is the job of adjuvant therapy: additional cancer treatment given after the primary treatment to lower the risk that the cancer will come back10. For high-risk melanoma that role already belongs to Keytruda, which Merck describes as a standard-of-care immunotherapy2 in this setting. The trial tested the vaccine as an add-on to Keytruda.

A treatment designed for one person

Tumours carry mutations, and some of those mutations produce neoantigens, which the US National Cancer Institute defines as new proteins that form on cancer cells when certain mutations occur in tumor DNA11, and they may play an important role in helping the body make an immune response against cancer cells11. Intismeran is built around that idea. Information from each patient's tumour and normal DNA is used to create an individualized treatment design, or "blueprint"1, and each dose is a synthetic mRNA coding for up to 34 neoantigens1. Once injected, the RNA-encoded neoantigen sequences are translated in the body and presented to the immune system1, which the companies call a key step in generating T-cell responses against cancer cells.

Making a different medicine for every patient takes time and tissue. In the trial, intismeran was successfully manufactured for more than 99% of the 757 patients5 assigned to it, and the median time to the first dose was 64 days5. Of 1,749 people screened, 302 (17.3%) were excluded for inadequate tumor samples5.

How the trial was built

INTerpath-001 is randomized and double-blind, with a placebo and an active comparator4, and it began in July 20234. Volunteers had surgically resected Stage IIB or IIC, III, or IV cutaneous melanoma4, no earlier systemic therapy for it, and no more than 13 weeks between their final surgery and their first dose of Keytruda4. In all, 1,137 patients were randomized 2:11, with 757 assigned to intismeran plus Keytruda and 380 to placebo plus Keytruda5. Intismeran was given as 1 mg every three weeks for up to nine doses1, with Keytruda at 400 mg every six weeks up to nine cycles1, about a year. The median age was 61 years5, and the analysis came at a median follow-up of 24.6 months1.

Reading the numbers

The main measure, recurrence-free survival, is the length of time from when the participant starts the study until either the cancer comes back, or the cancer spreads as assessed by the investigator, or death due to any cause4. Results are compared with a hazard ratio, a measure of how often a particular event happens in one group compared to how often it happens in another group, over time12. A ratio of 1 means no difference. The trial's ratio was 0.58 (95% CI, 0.45 to 0.75; two-sided p<0.001)1, which is where the 42% figure comes from.

Two years in, 82.2% of the combination group were alive without recurrence, against 70.0% on Keytruda alone1. The risk of the cancer spreading to distant organs, or death, fell by 38% (HR=0.62)1, with two-year distant metastasis-free survival of 88.5% versus 80.2%1.

Over the first six months the two arms looked alike (piecewise RFS HR 0.995), and the difference appeared after the immunisation course, when the companies report a 58% reduction (piecewise HR=0.42)1. Overall survival is not settled. Its hazard ratio was 0.77 (95% CI, 0.45 to 1.31)5, the data "were immature and did not meet the prespecified significance boundary"5, and the companies describe a favorable trend1. Cancer Network also notes that "Confidence intervals crossed 1 in several smaller subgroups"5.

Side effects

Treatment-related side effects were reported in 95.8% of the combination arm and 90.0% of the Keytruda arm5, and treatment-related grade 3 to 5 events (the more serious end of the scale) in 14.2% versus 13.4%1. The clearest differences were fever, in 52.2% versus 8.2%5, and injection site pain, in 51.0% versus 9.5%5. More people in the combination arm stopped a study drug because of treatment-related side effects, 14.0% versus 8.7%5. There were two treatment-related deaths (0.3%) in the combination arm, both attributed to pembrolizumab5, and none attributed to intismeran.

How it compares with the Phase 2b trial

The Phase 2b trial that came before, KEYNOTE-942, was smaller, enrolling 157 patients with resected stage IIIB to IV cutaneous melanoma9 (107 on the combination, 50 on Keytruda alone). Its five-year update, presented at the 2026 ASCO Annual Meeting, reported a 49% reduction in the risk of recurrence or death (HR=0.51)2 and five-year recurrence-free survival of 68.8% versus 49.1%9. The two are hard to set side by side. The Phase 3 result is a two-year read, the Phase 2b figure a five-year one, and the Phase 3 trial had more than seven times as many patients and included stage II disease, which the earlier trial did not.

What happens next

The companies say the results "have been accepted for publication in The New England Journal of Medicine"1. As of 23 October, the full results had not yet been published in a peer-reviewed journal6. Merck says that "we are engaging with regulatory authorities"1. Heather Shaw added a caution of her own: "This is an important step forward, but we still need longer follow-up to understand whether the benefit lasts"7.

The international trial included patients at the Western General Hospital in Edinburgh8. The INTerpath program has nine Phase 2 and Phase 3 clinical trials2, covering non-small cell lung cancer, bladder cancer and renal cell carcinoma among others.

Trivia

  1. Who shared the 2023 Nobel Prize in Physiology or Medicine for work behind mRNA vaccines? Katalin Karikó and Drew Weissman, for their discoveries concerning nucleoside base modifications13 that enabled effective mRNA vaccines against COVID-19.
  2. When were the key mRNA results of Karikó and Weissman published? In 2005, fifteen years before the COVID-19 pandemic13.
  3. When did Keytruda first win approval from the US Food and Drug Administration? On 4 September 201417, as the first anti-PD-1 therapy approved in the United States, for advanced melanoma.
  4. Which melanomas were excluded from INTerpath-001? Ocular or mucosal melanoma4.
  5. About how many skin melanomas did the World Health Organization attribute to excessive UV exposure worldwide in 2020? About 325,000, with about 57,000 deaths14 among them.
  6. At what UV index does the WHO recommend sun protection? When the index is 3 and above14.
  7. Where does melanoma rank among cancers in the UK? Cancer Research UK says it is the 5th most common cancer overall16 there.
  8. What share of UK melanoma cases does Cancer Research UK estimate are preventable? 86%15, based on 2015 figures.

Sources

  1. Merck and Moderna, Merck and Moderna Present Phase 3 INTerpath-001 Results for Intismeran Autogene Plus KEYTRUDA at ESMO 2026 Presidential Symposium, Merck.com (Business Wire), 22 October 2026. Accessed October 31, 2026.
  2. Merck and Moderna, Merck and Moderna Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA Met Endpoints of Recurrence-Free Survival (RFS) and Distant Metastasis-Free Survival (DMFS) in Patients With Completely Resected Stage IIB-IV Melanoma, Merck.com, 19 August 2026. Accessed October 31, 2026.
  3. Merck, Merck Showcases First-Time Pivotal Phase 3 Results From Oncology Pipeline and Continued Innovative Potential of Existing Portfolio at ESMO 2026, Merck.com, 13 October 2026. Accessed October 31, 2026.
  4. A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001), NCT05933577, ClinicalTrials.gov, US National Library of Medicine. Accessed October 31, 2026.
  5. Cancer Network Staff, INTerpath-001 Data Detail Survival, Subgroup, and Safety Findings in Melanoma, CancerNetwork, 24 October 2026. Accessed October 31, 2026.
  6. Emma Koppelman, Moderna-Merck personalized mRNA melanoma vaccine cuts relapse risk in late-stage trial, The National News Desk via KOMO News, 23 October 2026. Accessed October 31, 2026.
  7. Jane Kirby, World’s first mRNA cancer jab for melanoma cuts risk of death by 42%, PA via The Irish News, 23 October 2026. Accessed October 31, 2026.
  8. New vaccine could prevent skin cancer from returning, Institute of Genetics and Cancer, University of Edinburgh, 20 August 2026. Accessed October 31, 2026.
  9. Five-Year KEYNOTE-942 Results Show Durable Benefit of Intismeran Plus Pembrolizumab, HMP Global Learning Network, 27 August 2026. Accessed October 31, 2026.
  10. Adjuvant therapy, NCI Dictionary of Cancer Terms, National Cancer Institute. Accessed October 31, 2026.
  11. Neoantigen, NCI Dictionary of Cancer Terms, National Cancer Institute. Accessed October 31, 2026.
  12. Hazard ratio, NCI Dictionary of Cancer Terms, National Cancer Institute. Accessed October 31, 2026.
  13. Press release: The Nobel Prize in Physiology or Medicine 2023, Nobel Assembly at Karolinska Institutet, NobelPrize.org, 2 October 2023. Accessed October 31, 2026.
  14. Ultraviolet radiation, fact sheet, World Health Organization. Accessed October 31, 2026.
  15. Melanoma skin cancer statistics, Cancer Research UK. Accessed October 31, 2026.
  16. Risks and causes of melanoma, Cancer Research UK. Accessed October 31, 2026.
  17. Merck, Merck Receives Accelerated Approval of KEYTRUDA (pembrolizumab), the First FDA-Approved Anti-PD-1 Therapy, Merck.com, 4 September 2014. Accessed October 31, 2026.